Posterior Reversible Encephalopathy Syndrome in Patients With Cancer
- 1 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (7), 806-811
- https://doi.org/10.1634/theoncologist.2014-0149
Abstract
Background.: Posterior reversible encephalopathy syndrome (PRES) is characterized by neurologic symptoms with typical lesions on neuroimaging and may be associated with chemotherapy and immunosuppressive agents used in patients with cancer. We described the spectrum of PRES at a major cancer center. Methods.: We reviewed charts of adults with PRES between 2005 and 2011 at Memorial Sloan Kettering Cancer Center for clinical information and outcome. Results.: We identified 21 women (68%) and 10 men (median cohort age: 58 years). Solid tumors (n = 22, 71%) were more common than hematologic (n = 8) or primary brain malignancies (n = 1). Prior brain irradiation (16%) and central nervous system metastases (10%) were uncommon. There were 55% who received chemotherapy or targeted therapy within the month preceding PRES, including 6 patients who received bevacizumab; PRES followed allogeneic stem cell transplantation in 5 (16%). Presenting symptoms included confusion (71%), seizure (58%), and headache (48%). Maximum systolic and diastolic blood pressures were similar among patients grouped by cancer type, chemotherapy or bevacizumab use, and atypical imaging. Moreover, 37% of patients with both magnetic resonance imaging (MRI) and computed tomography (CT) had normal CT concurrent with PRES on MRI, and 84% returned to neurologic baseline at a median of 7.5 days (range: 1–167 days) from onset. Successful anticonvulsant taper was achieved in 51%. Chemotherapy rechallenge was attempted in 41% without recurrent PRES. Autopsy revealed nonspecific changes isolated to radiographically affected areas in one of two patients. Conclusion.: Recent chemotherapy, particularly bevacizumab, is common in cancer patients with PRES. Clinical and radiographic presentations may vary; MRI appears more sensitive than CT. Anticonvulsant taper and chemotherapy rechallenge is often possible. Implications for Practice: Posterior reversible encephalopathy syndrome is characterized by neurologic symptoms with typical lesions on neuroimaging and may be associated with chemotherapy and immunosuppressive agents used in patients with cancer. Clinical and radiographic presentations are protean, and magnetic resonance imaging is more sensitive than computed tomography. Recovery is common, and many patients can be successfully rechallenged with the apparently offending chemotherapy agent or regimen.Keywords
This publication has 38 references indexed in Scilit:
- Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patternsZeitschrift für Neurologie, 2011
- Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatmentQJM: An International Journal of Medicine, 2011
- Posterior reversible encephalopathy syndrome in childhood cancerAnnals Of Oncology, 2010
- MRI Features of Posterior Reversible Encephalopathy Syndrome in 33 PatientsJournal of Neuroimaging, 2009
- Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinomaMedical Oncology, 2009
- Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical SignificanceTransplantation and Cellular Therapy, 2007
- The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patientsBrain, 2007
- Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon CancerArchives of Neurology, 2006
- Life-threatening neurological complications after bone marrow transplantation in childrenBone Marrow Transplantation, 2004
- Severe Tacrolimus Leukoencephalopathy after Liver Transplantation2003